Icatibanto Piramal (Icatibant)

Icatibant is a competitive antagonist of the bradykinin B2 receptor. By blocking this receptor on blood‑vessel walls, it prevents bradykinin‑induced increases in vascular permeability, thereby limiting the fluid leakage that causes swelling in hereditary angioedema.

The specific dose and administration schedule are determined by the prescribing clinician based on the patient’s condition, weight, and severity of the attack. Icatibanto Piramal is supplied as a ready‑to‑use injectable solution.

Safety data for icatibant during pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

The main alternative class is C1‑esterase inhibitor concentrates, which replace the deficient protein. Icatibant directly blocks bradykinin receptors, offering rapid symptom relief without the need for plasma‑derived products. Choice of therapy depends on patient preference, attack severity, and clinical guidelines.

Icatibanto Piramal must be stored refrigerated between 2 °C and 8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not use if the product has been exposed to temperatures outside this range.

The medication is supplied as a sterile solution for subcutaneous injection. It can be administered by a healthcare professional or, after appropriate training, self‑injected by the patient into the abdominal wall or thigh using the pre‑filled syringe.

Serious adverse events include anaphylaxis, severe angioedema unrelated to the underlying disease, and hypotension. Patients should be monitored after injection for any signs of systemic allergic reaction and instructed to seek immediate medical attention if symptoms develop.

Icatibanto Piramal is contraindicated in individuals with known hypersensitivity to icatibant or any of the excipients in the formulation. Caution is also advised for patients with a history of severe allergic reactions or those receiving ACE inhibitors without close monitoring.